Consistent results were also obtained from the IC50 differences of the two inhibitors targeting DNA replication (doxorubicin and etoposide) and an inhibitor targeting nucleic acid synthesis (gemcitabine) in different SRSF11-expressing HCC cells (Figure 9F–H). Here, SRSF11 is linked to hepatocellular carcinoma.